Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Measuring Oncological Value of Exercise and Atorvastatin (MOVES)
2024-515109-24-00Phase 3Authorised
- Sponsor
- Pirkanmaan hyvinvointialue
- Start
- Aug 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3 trial of Lipistad in breast cancer, Malignant ovarian neoplasm (OC), prostate cancer (PCa) and 1 more, sponsored by Pirkanmaan hyvinvointialue. Primary endpoints: Cancer progression and Overall mortality. Planned start Aug 2024; status: authorised.
02
Drugs
Lipistad
03
Conditions
breast cancerMalignant ovarian neoplasm (OC)prostate cancer (PCa)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2024-515109-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515109-24-00.